Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel has been approved for routine use in relapsed or refractory diffuse large B-cell lymphoma after...

This interim analysis provides support for considering carfilzomib, lenalidomide, and dexamethasone therapy in patients with newly diagnosed multiple myeloma who completed any induction regimen...

In November, 2022, NHS England reported the worst ever waiting times for cancer treatment (figure 1).1,2 In the past 12 months, 69 000 patients in...

The recent Essay by Pat Price and colleagues1 and the accompanying Comment2 in The Lancet Oncology add to what is now a clarion call...

Research commissioned by the UK Fire Brigades Union is currently underway at the University of Central Lancashire (UCLan, Preston, UK) into the impact of...

This study provides evidence that right-sided hemicolectomy is not indicated after complete resection of an appendiceal NET of 1–2 cm in size by appendectomy,...

Mashup Score:7

The Lancet Oncology

Tattoos, inks, and cancer - 5 days

Mashup Score:7

The introduction in the dermis of exogenous pigments and dyes to obtain a permanent design (tattooing) represents a unique in-vivo situation, where a large...

The sex ratio for childhood cancer in India has a bias towards boys at the level of diagnosis, which is more pronounced in northern...

Not all mutations related to TMB-H can enhance antitumour immune response. More composite biomarkers should be investigated (eg, mTMB signature) to tailor treatment with...

This interim analysis provides support for considering carfilzomib, lenalidomide, and dexamethasone therapy in patients with newly diagnosed multiple myeloma who completed any induction regimen...

  • 1613823035416678403 Profile photo of Madelyn

    Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial https://t.co/AwQ3ypKrA6 - view on twitter